Royal Marsden leads as first UK site for new paediatric clinical trial following ground-breaking research
A new drug called Fadraciclib will be available to eligible young patients with aggressive neuroblastoma.
The European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumours (ESMART) trial has been designed collaboratively within the Innovative Therapies for Children with Cancer (ITCC) European paediatric early phase clinical trial consortium, in which UK centres and investigators play key roles. Funded in the UK by Cancer Research UK, trial management is by the Children’s Cancer Trials Team at the University of Birmingham Cancer Research Clinical Trials Unit (CR-CTU). It started in France in the summer of 2017, with the first UK arm opening at The Royal Marsden in December 2019. Following opening The Royal Marsden, the ESMART trial is now open at the Royal Manchester Children’s Hospital and Birmingham Children’s Hospital with further sites due to open in Newcastle and Great Ormond Street Hospital over the next few months.
Supported by The Royal Marsden Cancer Charity
The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden, a world-leading cancer centre. It ensures Royal Marsden nurses, doctors and research teams can provide the very best care and develop life-saving treatments, which are used across the UK and around the world. From funding state-of-the-art equipment and ground-breaking research, to creating the very best patient environments, The Royal Marsden Cancer Charity will never stop looking for ways to improve the lives of people affected by cancer.